









Markets
/
Stocks
/
nasdaq-femy
/

Femasys Inc

FEMY

0.508USD

+0.023+4.74%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

24.03MMarket Cap

LossP/E TTM



Femasys Inc

0.508

+0.023+4.74%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Femasys Inc

Currency: USD Updated: 2026-02-06

Key Insights

Femasys Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 123 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 5.17.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Femasys Inc's Score

Industry at a Glance

Industry Ranking

123 / 205

Overall Ranking

321 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Femasys Inc Highlights

StrengthsRisks

Femasys Inc. is a biomedical company. The Company is focused on addressing the unmet needs of women worldwide with a broad portfolio of in-office, accessible, and therapeutic and diagnostic solutions. The Company has two lead product candidates: FemBloc and FemaSeed. FemBloc is a permanent birth control solution in development. Its permanent birth control solution in development includes its FemBloc system, which features dual intrauterine directional delivery targeting both fallopian tubes with a degradable blended biopolymer. FemaSeed is an artificial insemination infertility treatment. Its artificial insemination solution in development includes its FemaSeed product candidate for artificial insemination, which features single intrauterine directional delivery. It also developed FemCerv, which is an endocervical tissue sampler for cervical cancer diagnosis; FemVue, which is a companion diagnostic for fallopian tube assessment; FemCath, which is an intrauterine catheter, and FemChec.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 35.06% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 1.63M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1.63M.

Overvalued

The company’s latest PE is -0.74, at a high 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 1.42M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.15.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

5.167

Target Price

+856.79%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Femasys Inc is 5.94, ranking 181 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 729.39K, representing a year-over-year increase of 31.44%, while its net profit experienced a year-over-year increase of 22.45%.

Score

Industry at a Glance

Previous score

5.94

Change



Financials

6.17

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.90

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.71

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Femasys Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Femasys Inc is 6.05, ranking 173 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.74, which is -57.04% below the recent high of -0.32 and -436.67% above the recent low of -3.97.

Score

Industry at a Glance

Previous score

6.05

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 123/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Femasys Inc is 8.00, ranking 60 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 6.00, with a high of 6.50 and a low of 3.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

5.167

Target Price

+856.79%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

Femasys Inc

FEMY

Stryker Corp

SYK

Medtronic PLC

MDT

Dexcom Inc

DXCM

Abbott Laboratories

ABT

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Femasys Inc is 6.44, ranking 146 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 0.66 and the support level at 0.42, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.28

Change

0.16

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.010

Sell

RSI(14)

36.763

Neutral

STOCH(KDJ)(9,3,3)

16.396

Neutral

ATR(14)

0.048

Low Volatility

CCI(14)

-93.226

Neutral

Williams %R

88.581

Oversold

TRIX(12,20)

-1.070

Sell

StochRSI(14)

74.730

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.514

Sell

MA10

0.544

Sell

MA20

0.589

Sell

MA50

0.708

Sell

MA100

0.672

Sell

MA200

0.762

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Femasys Inc is 3.00, ranking 134 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 9.41%, representing a quarter-over-quarter decrease of 13.87%. The largest institutional shareholder is The Vanguard, holding a total of 1.42M shares, representing 2.42% of shares outstanding, with 20.59% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Chernett (Jorey)

3.03M

+86.81%

Dauntless Investment Group, LLC

1.73M

-25.35%

The Vanguard Group, Inc.

Star Investors

951.87K

Uzialko (Edward R Jr.)

1.22M

Alumni Capital Management LLC

931.90K

Lee-Sepsick (Kathy)

432.85K

+12.63%

Geode Capital Management, L.L.C.

258.23K

+2.72%

Clear Creek Financial Management, LLC

138.90K

-50.71%

Currie (Daniel Scott)

109.24K

+21.88%

BlackRock Institutional Trust Company, N.A.

94.06K

+1.79%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Femasys Inc is 1.28, ranking 194 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is -2.50. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.